Prestige Biopharma (PBP) is a Singapore-based biopharmaceutical company focusing on discovery, research, development and registration of biosimilars, first-in-class antibody drugs and vaccines, with the aim of finding cures and preventive medicines for devastating diseases, and to provide through our partners access to affordable quality biologics to the patients of the world.
Prestige Biopharma strives to become a global innovator through the development of first-in-class antibody therapeutics including PBP1510 anti-PAUF mAb for pancreatic cancer (INN-ulenistamab) that obtained orphan designation from FDA, EMA and MFDS. Another 10 bispecific antibody projects based on PBP’s proprietary oncology therapeutic targets, PAUF and CTHRC1, are currently in development. Prestige Biopharma’s rich portfolio of biosimilars in various stages consist of the lead program, HD201, a trastuzumab biosimilar, currently under review by Health Canada and Korean MFDS, HD204, a bevacizumab biosimilarin Phase 3 of clinical development and planned to be filed in Q4/2023, PBP1502 an adalimumab biosimilar currently in phase I. Other biosimilars in the pipeline include aflibercept, eculizumab, ipilimumab, nivolumab, pembrolizumab, pertuzumab, and others.
Prestige Biopharma’s area of capabilities also includes full value chain technological platform for drug discovery leading to expedited development, from drug discovery, non-clinical and clinical development, to regulatory registration and global commercialization together with our partners.
Prestige Biopharma, together with Prestige Biologics, also expanded its business into development and manufacturing of vaccines at global scale vaccine center, starting with partnered commercial production of COVID-19 vaccines, and collaboration in developing next generation vaccines for potential future pandemics.
Prestige Biopharma’s dedicated manufacturing facility, Prestige Biologics, is a biopharmaceutical CDEMO (Contract Development Engineering Manufacturing Organization) that provides complete solutions to the development and manufacturing requirements in drug discovery from early stage to product registration and commercialization. With its fully established antibody drug and vaccine manufacturing capabilities, Prestige Biologics offers CDEMO services in which customized engineering solutions are provided for manufacturing process in a customized manufacturing suite speed-built with its proprietary technology, ALITA Smart BioFactory™. Currently, a total production capacity of 154,000L with Full Single-Use System and ALITA Smart BioFactory™ is available for global clients.
Prestige Biopharma strives to become a global innovator through the development of first-in-class antibody therapeutics including PBP1510 anti-PAUF mAb for pancreatic cancer (INN-ulenistamab) that obtained orphan designation from FDA, EMA and MFDS. Another 10 bispecific antibody projects based on PBP’s proprietary oncology therapeutic targets, PAUF and CTHRC1, are currently in development. Prestige Biopharma’s rich portfolio of biosimilars in various stages consist of the lead program, HD201, a trastuzumab biosimilar, currently under review by Health Canada and Korean MFDS, HD204, a bevacizumab biosimilarin Phase 3 of clinical development and planned to be filed in Q4/2023, PBP1502 an adalimumab biosimilar currently in phase I. Other biosimilars in the pipeline include aflibercept, eculizumab, ipilimumab, nivolumab, pembrolizumab, pertuzumab, and others.
Prestige Biopharma’s area of capabilities also includes full value chain technological platform for drug discovery leading to expedited development, from drug discovery, non-clinical and clinical development, to regulatory registration and global commercialization together with our partners.
Prestige Biopharma, together with Prestige Biologics, also expanded its business into development and manufacturing of vaccines at global scale vaccine center, starting with partnered commercial production of COVID-19 vaccines, and collaboration in developing next generation vaccines for potential future pandemics.
Prestige Biopharma’s dedicated manufacturing facility, Prestige Biologics, is a biopharmaceutical CDEMO (Contract Development Engineering Manufacturing Organization) that provides complete solutions to the development and manufacturing requirements in drug discovery from early stage to product registration and commercialization. With its fully established antibody drug and vaccine manufacturing capabilities, Prestige Biologics offers CDEMO services in which customized engineering solutions are provided for manufacturing process in a customized manufacturing suite speed-built with its proprietary technology, ALITA Smart BioFactory™. Currently, a total production capacity of 154,000L with Full Single-Use System and ALITA Smart BioFactory™ is available for global clients.
Focus Areas
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
